VB10.16

BIOLOGICAL3 trials

Sponsors

Nykode Therapeutics ASA

Conditions

Cervical CancerCervix CancerHNSCCHPV Positive Oropharyngeal Squamous Cell CarcinomaHPV-Related Cervical CarcinomaHPV-Related Malignancy

Phase 1

Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma

RecruitingNCT06016920

Nykode Therapeutics ASAHNSCC, HPV Positive Oropharyngeal Squamous Cell Carcinoma

Start: 2023-12-19End: 2028-01-31Target: 51Updated: 2024-12-17

Phase 2

Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer

CompletedNCT04405349

Nykode Therapeutics ASACervical Cancer, Cervix Cancer

Start: 2020-07-01End: 2023-11-24Updated: 2023-12-15

Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.

WithdrawnNCT06099418

Nykode Therapeutics ASACervical Cancer, HPV-Related Cervical Carcinoma, HPV-Related Malignancy

Start: 2024-04-18End: 2028-05-31Updated: 2024-09-20

Related Papers

Integrative analysis of VB10.16 and atezolizumab in advanced HPV16-positive cervical cancer: Linking biomarker insights to clinical outcomes.

Journal of Clinical Oncology2025-05-28

Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a study

Journal for ImmunoTherapy of Cancer2025-01-018 citations

Abstract A003: High-throughput TCR sequencing demonstrates induction of long-lasting HPV16-specific T cell responses in VB10.16 vaccinated advanced cervical cancer patients

Cancer Immunology Research2023-12-011 citations

667 Predictive value of circulating tumor DNA in patients with advanced HPV16-positive cervical cancer treated with VB10.16 in combination with atezolizumab

Regular and Young Investigator Award Abstracts2023-10-311 citations

669 Use of HPV16 circulating tumor DNA detected in liquid biopsies to predict response in patients with advanced HPV16-positive cervical cancer

Regular and Young Investigator Award Abstracts2022-11-01